{"id":"NCT00265395","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","officialTitle":"A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2005-12-14","resultsPosted":"2009-07-08","lastUpdate":"2017-04-05"},"enrollment":1428,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)","otherNames":["(a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg.","(b) SCH 18908; Rebetol; REBETOL."]},{"type":"DRUG","name":"Combination of pegylated interferon alfa-2b and ribavirin","otherNames":["(a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg.","(b) SCH 18908; Rebetol; REBETOL."]}],"arms":[{"label":"Standard therapy","type":"ACTIVE_COMPARATOR"},{"label":"Extended therapy","type":"EXPERIMENTAL"}],"summary":"This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic hepatitis C. It is designed to evaluate whether 72 weeks of treatment with PEG-Intron plus Rebetol is more effective than 48 weeks of treatment in subjects with Genotype 1 chronic hepatitis C who exhibit a slow response to treatment.","primaryOutcome":{"measure":"Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.","timeFrame":"48 or 72 weeks of treatment plus 24 weeks of follow-up.","effectByArm":[{"arm":"Standard Therapy (48-week Treatment)","deltaMin":37,"sd":null},{"arm":"Extended Therapy (72-week Treatment)","deltaMin":35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6445"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20683847"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":1427},"commonTop":["INFLUENZA LIKE ILLNESS","PYREXIA","HEADACHE","ASTHENIA","FATIGUE"]}}